FDA Adverse Event Injury Summary report: N

INFUSE BONE GRAFT

MDR report key: 3970431 · Received July 31, 2014

Report

Report Number
1030489-2014-03370
Event Type
Injury
Date Received
July 31, 2014
Report Date
October 26, 2015
Manufacturer
MEDTRONIC SOFAMOR DANEK USA, INC
Product Code
NEK
PMA / PMN Number
P000058
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
ATTORNEY

Narratives

Additional Manufacturer Narrative · 1

(B)(6).

Additional Manufacturer Narrative · 1

(B)(4). NEITHER THE DEVICE NOR FILMS OF APPLICABLE IMAGING STUDIES WERE RETURNED TO THE MANUFACTURER FOR EVALUATION. THEREFORE, WE ARE UNABLE TO DETERMINE THE DEFINITIVE CAUSE OF THE REPORTED EVENT. PRODUCTS FROM MULTIPLE MANUFACTURERS WERE IMPLANTED DURING THE PROCEDURE. ALTHOUGH IT IS UNKNOWN IF ANY OF THE DEVICES CONTRIBUTED TO THE REPORTED EVENT, WE ARE FILING THIS MDR FOR NOTIFICATION PURPOSES.

Description of Event or Problem · 1

IT WAS REPORTED THAT THE PATIENT DEVELOPED UNSPECIFIED INJURIES FOLLOWING THE USE OF RHBMP-2/ACS IN AN UNSPECIFIED SPINAL FUSION SURGERY. NO ADDITIONAL INFORMATION WAS REPORTED.

Description of Event or Problem · 1

IT WAS REPORTED THAT ON (B)(6) 2009: THE PATIENT PRESENTED WITH FOLLOWING PRE-OP DIAGNOSIS: CERVICAL PSEUDOARTHROSIS, INSTABILITY C4-5, C5-6, AND UNDERWENT THE FOLLOWING PROCEDURE: POSTERIOR CERVICAL FUSION WITH FACET SCREW ROD INSTRUMENTATION C4 TO 6 AND POSTEROLATERAL BONE GRAFT USING INFUSE BONE MORPHOGENIC PROTEIN. AS PER THE OP NOTES, THE INFUSE BONE MORPHOGENIC PROTEIN AND GELFOAM WAS PLACED OVER THE DECORTICATED FACET BILATERALLY FOR THE BONE FUSION. THIS WAS DONE AFTER COPIOUS BACITRACIN PULSE LAVAGE IRRIGATION WAS DONE TO WASH THE WOUND OUT. HEMOSTASIS WAS ENSURED AND THE WOUND WAS CLOSED. NO PATIENT COMPLICATIONS WERE REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
448126 INFUSE BONE GRAFT FILLER, RECOMBINANT HUMAN BONE MORPHOGENETIC PROTEIN, COLLAGEN SCAFFOLD WITH MET NEK MEDTRONIC SOFAMOR DANEK USA, INC NA M110803AAF

Patients

Seq Age Sex Outcome Treatment
1 Other